钠-葡萄糖协同转运体-2抑制剂empagliflozin对一名射血分数保留型心力衰竭患者病情进展的影响

Q4 Medicine

Vnitrni lekarstvi Pub Date : 2023-01-01 DOI:10.36290/vnl.2023.032

Filip Málek

{"title":"钠-葡萄糖协同转运体-2抑制剂empagliflozin对一名射血分数保留型心力衰竭患者病情进展的影响","authors":"Filip Málek","doi":"10.36290/vnl.2023.032","DOIUrl":null,"url":null,"abstract":"Sodiumglucose co-transporter 2 inhibitors - gliflozins - have a scientific evidence on efficacy in patients with heart failure regardless left ventricular ejection fraction. Gliflozins They reduced combined endpoint of cardiovascular mortality and heart failure hospitalization also in patients with heart failure and left ventricular ejection fraction above 40 %. We report a case study of a patient with new onset heart failure. Early initiation of therapy with empagliflozin was associated with an improvement of symptoms and laboratory parameters including NT-proBNP level.","PeriodicalId":23501,"journal":{"name":"Vnitrni lekarstvi","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of sodium-glucose co-transporter-2 inhibitor empagliflozin on disease progression in a patient with heart failure and preserved ejection fraction.\",\"authors\":\"Filip Málek\",\"doi\":\"10.36290/vnl.2023.032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sodiumglucose co-transporter 2 inhibitors - gliflozins - have a scientific evidence on efficacy in patients with heart failure regardless left ventricular ejection fraction. Gliflozins They reduced combined endpoint of cardiovascular mortality and heart failure hospitalization also in patients with heart failure and left ventricular ejection fraction above 40 %. We report a case study of a patient with new onset heart failure. Early initiation of therapy with empagliflozin was associated with an improvement of symptoms and laboratory parameters including NT-proBNP level.\",\"PeriodicalId\":23501,\"journal\":{\"name\":\"Vnitrni lekarstvi\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vnitrni lekarstvi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36290/vnl.2023.032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vnitrni lekarstvi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36290/vnl.2023.032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

葡萄糖钠协同转运体 2 抑制剂（格列酮类）对心力衰竭患者的疗效有科学依据，无论其左心室射血分数如何。对于左心室射血分数超过 40% 的心力衰竭患者，格列酮类药物也能降低心血管死亡率和心力衰竭住院率的综合终点。我们报告了一例新发心衰患者的研究。尽早开始使用恩格列净（empagliflozin）治疗与症状和实验室指标（包括NT-proBNP水平）的改善有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of sodium-glucose co-transporter-2 inhibitor empagliflozin on disease progression in a patient with heart failure and preserved ejection fraction.

Sodiumglucose co-transporter 2 inhibitors - gliflozins - have a scientific evidence on efficacy in patients with heart failure regardless left ventricular ejection fraction. Gliflozins They reduced combined endpoint of cardiovascular mortality and heart failure hospitalization also in patients with heart failure and left ventricular ejection fraction above 40 %. We report a case study of a patient with new onset heart failure. Early initiation of therapy with empagliflozin was associated with an improvement of symptoms and laboratory parameters including NT-proBNP level.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vnitrni lekarstvi Medicine-Internal Medicine

CiteScore

0.50

自引率

0.00%

发文量

104

期刊介绍： Vnitřní lékařství je tiskovým orgánem České internistické společnosti České lékařské společnosti Jana Evangelisty Purkyně a Slovenskej internistickej spoločnosti Slovenskej lekárskej spoločnosti. Je vydáván nepřetržitě od roku 1955. Časopis vychází jako měsíčník, tedy 12krát do roka a podle potřeby jsou v běžném ročníku vydávána jeho suplementa, která jsou obsahově zaměřena k určitému tématu. Tematicky je časopis zaměřen široce na oblast interní medicíny se zvláštní pozorností ke kardiologii, diabetologii a poruchám metabolizmu.